Omar S. Sarkar

Omar S. Sarkar

Auto-generated profile, based on publicly available information

Omar S. Sarkar

Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Science Advances
Verified
Journal Article
Open access
OSOmar S. Sarkar
Omar S. Sarkar
HDHoward Donninger
Howard Donninger
NRNuman Al Rayyan
Numan Al Rayyan
LCLewis C. Chew
Lewis C. Chew
BSBryce Stamp
Bryce Stamp
KYKavitha Yaddanapudi
Kavitha Yaddanapudi
Immune checkpoint inhibitor (ICI) therapy is effective against many cancers for a subset of patients; a large percentage of patients remain unresponsive to this therapy. One contributing factor to ICI resistance is accumulation of monocytic myeloid-derived suppressor cells (M-MDSCs), a subset of innate immune cells with potent immunosuppressive activity against T lymphocytes. Here, using lung, melanoma, and breast cancer mouse models, we show that CD73-expressing M-MDSCs in the tumor microenvironment (TME) exhibit superior T cell suppressor function. Tumor-derived PGE 2 , a prostaglandin, directly induces CD73 expression in M-MDSCs via both Stat3 and CREB. The resulting CD73 overexpression induces elevated levels of adenosine, a nucleoside with T cell–suppressive activity, culminating in suppression of antitumor CD8 + T cell activity. Depletion of adenosine in the TME by the repurposed drug PEGylated adenosine deaminase (PEG-ADA) increases CD8 + T cell activity and enhances response to ICI therapy. Use of PEG-ADA can therefore be a therapeutic option to overcome resistance to ICIs in cancer patients.